QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
$15.00
$14.97
$3.06
$15.00
$521.45M1601,442 shs247,800 shs
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
$1.95
-1.5%
$2.38
$1.42
$12.01
$102.16M1.22.79 million shs858,558 shs
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
$19.00
$18.88
$8.82
$21.86
$794.77M0.881.36 million shsN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$1.70
-9.4%
$2.41
$0.92
$3.79
$417.38M1.274.48 million shs4.57 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
-4.13%-14.69%-19.39%-2.23%-83.33%
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
0.00%0.00%0.00%0.00%+10.14%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-5.08%-10.53%-28.08%+41.67%-22.41%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
3.9233 of 5 stars
3.02.00.04.61.82.51.3
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
0.332 of 5 stars
1.00.00.03.90.01.70.6
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
1.0183 of 5 stars
3.01.00.00.01.91.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
N/AN/AN/AN/A
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
2.00
Hold$5.00156.41% Upside
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
2.00
Hold$19.864.51% Upside
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.00
Hold$5.00194.99% Upside

Current Analyst Ratings

Latest AVEO, EBS, LXRX, and ICPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2024
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
4/11/2024
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
3/7/2024
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$5.00
(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
$42.29M12.33N/AN/A$1.33 per share11.28
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
$1.05B0.10$0.83 per share2.34$12.51 per share0.16
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
$285.71M2.78N/AN/A$1.72 per share11.05
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$1.20M347.81N/AN/A$0.38 per share4.46

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/A
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
-$760.50M-$14.83N/AN/AN/A-72.11%-37.35%-14.81%5/14/2024 (Estimated)
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
$221.82M-$1.48N/A9.84N/A-19.39%-77.48%-11.99%N/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$177.12M-$0.80N/AN/AN/A-14,573.20%-138.54%-71.29%5/7/2024 (Estimated)

Latest AVEO, EBS, LXRX, and ICPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/11/2024Q4 2023
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.23-$0.20+$0.03-$0.20$0.68 million$0.70 million
3/6/2024Q4 2023
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
-$0.33-$0.77-$0.44-$0.59$247.63 million$276.60 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
N/AN/AN/AN/AN/A
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
N/AN/AN/AN/AN/A
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
N/AN/AN/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
0.94
2.37
2.35
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
0.69
1.04
0.54
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
3.12
4.22
2.52
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
1.07
5.60
5.58

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
49.95%
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
78.40%
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
83.81%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
74.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AVEO Pharmaceuticals, Inc. stock logo
AVEO
AVEO Pharmaceuticals
11434.76 million33.62 millionOptionable
Emergent BioSolutions Inc. stock logo
EBS
Emergent BioSolutions
1,60052.39 million46.58 millionOptionable
Intercept Pharmaceuticals, Inc. stock logo
ICPT
Intercept Pharmaceuticals
34141.83 million39.19 millionOptionable
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
285246.24 million235.16 millionOptionable

AVEO, EBS, LXRX, and ICPT Headlines

SourceHeadline
All You Need to Know About Lexicon (LXRX) Rating Upgrade to BuyAll You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy
zacks.com - April 16 at 1:01 PM
Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded by StockNews.com to SellLexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded by StockNews.com to Sell
americanbankingnews.com - April 16 at 3:42 AM
Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to "Sell" by StockNews.comLexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to "Sell" by StockNews.com
marketbeat.com - April 15 at 11:09 PM
Needham & Company LLC Reiterates "Hold" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)Needham & Company LLC Reiterates "Hold" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)
americanbankingnews.com - April 13 at 6:16 AM
Lexicon Pharmaceuticals (LXRX) Hold Rating Reiterated at Needham & Company LLCLexicon Pharmaceuticals' (LXRX) Hold Rating Reiterated at Needham & Company LLC
marketbeat.com - April 11 at 8:31 AM
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Up 5.9%Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Up 5.9%
marketbeat.com - April 4 at 2:03 PM
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceLexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 3 at 8:32 AM
Lexicon Pharmaceuticals (NASDAQ:LXRX)  Shares Down 3.7% Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Down 3.7%
marketbeat.com - April 1 at 2:58 PM
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Up 11.1%Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Up 11.1%
marketbeat.com - March 27 at 12:44 PM
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & ExpoClinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
globenewswire.com - March 25 at 9:20 AM
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Down 5.8%Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Down 5.8%
marketbeat.com - March 22 at 5:07 PM
LXRX Apr 2024 5.000 putLXRX Apr 2024 5.000 put
finance.yahoo.com - March 16 at 7:59 PM
Lexicon (LXRX) Dips on Post Hoc Analysis Data on SotagliflozinLexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
zacks.com - March 13 at 1:46 PM
Path forward for sotagliflozin becomes clear after FDA feedbackPath forward for sotagliflozin becomes clear after FDA feedback
thepharmaletter.com - March 12 at 6:19 PM
Lexicon Announces Positive Data Of InTandem3 Study In Type 1 Diabetes Patients With CKD; Stock DownLexicon Announces Positive Data Of InTandem3 Study In Type 1 Diabetes Patients With CKD; Stock Down
markets.businessinsider.com - March 12 at 1:18 PM
Lexicon stock slides 8% after rallying 30% in prior sessionLexicon stock slides 8% after rallying 30% in prior session
seekingalpha.com - March 12 at 1:18 PM
5 years after initial FDA rejection, Lexicon prepares to resubmit Type 1 diabetes hopeful Zynquista5 years after initial FDA rejection, Lexicon prepares to resubmit Type 1 diabetes hopeful Zynquista
fiercepharma.com - March 12 at 8:16 AM
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney DiseaseNew Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
finance.yahoo.com - March 12 at 8:16 AM
Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core AssetLexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset
seekingalpha.com - March 12 at 4:01 AM
Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for SotagliflozinLexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin
marketwatch.com - March 11 at 10:53 AM
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDALexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
finance.yahoo.com - March 11 at 10:53 AM
Lexicon: Q4 Earnings SnapshotLexicon: Q4 Earnings Snapshot
washingtonpost.com - March 11 at 10:53 AM
Lexicon Pharmaceuticals: Q4 Earnings InsightsLexicon Pharmaceuticals: Q4 Earnings Insights
benzinga.com - March 11 at 10:53 AM
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue EstimatesLexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
zacks.com - March 11 at 9:26 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AVEO Pharmaceuticals logo

AVEO Pharmaceuticals

NASDAQ:AVEO
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.
Emergent BioSolutions logo

Emergent BioSolutions

NYSE:EBS
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Intercept Pharmaceuticals logo

Intercept Pharmaceuticals

NASDAQ:ICPT
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..
Lexicon Pharmaceuticals logo

Lexicon Pharmaceuticals

NASDAQ:LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.